Latest Product Pipeline News

Yowie Group’s FY26 loss narrowed sharply after cost reductions and a non-cash loan impairment reversal, but revenue fell 27% and operating cash flow turned deeply negative. The confectionery maker remains loss-making, has negative net assets and faces uncertainty over funding, supply and the return of its ASX quotation.

ION Video has secured an oversubscribed $4.25 million placement to fund independent trials of its video technology, with directors and management committing a further $1.2 million subject to shareholder approval. The capital will be used to test whether ION’s architecture can deliver measurable technical and financial benefits in real operating environments.

New Hope delivered more coal, expanded its resource base and declared a 30-cent final dividend, but lower realised prices and higher costs cut FY26 profit by 63.4%. The results leave investors weighing near-term earnings pressure against a larger production pipeline.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Evolution Mining has taken a significant step toward its full acquisition of Carnaby Resources by acquiring a 13.7% stake from the QIC Queensland Critical Minerals Fund through a share issue, reinforcing its position as Carnaby’s largest shareholder.

Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

Atomo Diagnostics has appointed Dr Cheri Walker as interim CEO, replacing founder John Kelly who steps down after 15 years. The leadership change aligns with the company's shift towards commercial growth in the US and Europe.

XRF Scientific reported an 8% revenue increase to $64.4 million and a modest 1% rise in net profit after tax for FY26, underpinned by strong performances in Precious Metals and Capital Equipment divisions and the strategic acquisition of Bruker’s CGA business.

REA Group Ltd (ASX:REA) posted a robust FY26 with revenue up 7% to A$1.793 billion and core net profit rising 15% to A$682 million, supported by record audience engagement and strategic AI investments.